LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Home・Aandelen Lijst・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Gesloten

1.33 3.1

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.33

Max

1.34

Belangrijke statistieken
By Trading Economics
Inkomsten	17M -26M
Werknemers	171
EBITDA	19M -23M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+55.04% upside

Dividenden
By Dow Jones
Volgende Winsten	12 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-24M 78M
Vorige openingsprijs	-1.77
Vorige sluitingsprijs	1.33

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

1.43 / 1.6 Steun & Weerstand

Pliant Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 mrt 2026, 19:32 UTC

Acquisities, Fusies, Overnames

Diana Shipping Increases Offer to Acquire Genco -- Update

6 mrt 2026, 17:44 UTC

Acquisities, Fusies, Overnames

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

7 mrt 2026, 02:30 UTC

Belangrijke Nieuwsgebeurtenissen

Iran War Is Kicking India When It's Already Down -- Barrons.com

6 mrt 2026, 22:26 UTC

Belangrijke Nieuwsgebeurtenissen

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6 mrt 2026, 22:07 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6 mrt 2026, 22:03 UTC

Marktinformatie

Global Equities Roundup: Market Talk

6 mrt 2026, 22:03 UTC

Marktinformatie

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6 mrt 2026, 21:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Financial Services Roundup: Market Talk

6 mrt 2026, 21:37 UTC

Winsten

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6 mrt 2026, 21:25 UTC

Belangrijke Nieuwsgebeurtenissen

How The Iran War Impacts Ukraine. -- Barrons.com

6 mrt 2026, 21:17 UTC

Winsten

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6 mrt 2026, 20:50 UTC

Winsten

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6 mrt 2026, 20:46 UTC

Winsten

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6 mrt 2026, 20:31 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6 mrt 2026, 20:18 UTC

Marktinformatie

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6 mrt 2026, 20:12 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6 mrt 2026, 19:10 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6 mrt 2026, 18:54 UTC

Marktinformatie

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6 mrt 2026, 18:44 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6 mrt 2026, 18:08 UTC

Winsten

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mrt 2026, 18:04 UTC

Winsten

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mrt 2026, 18:04 UTC

Winsten

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mrt 2026, 17:49 UTC

Marktinformatie

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6 mrt 2026, 17:46 UTC

Belangrijke Nieuwsgebeurtenissen

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6 mrt 2026, 17:40 UTC

Marktinformatie

Winsten

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6 mrt 2026, 17:40 UTC

Winsten

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mrt 2026, 17:32 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6 mrt 2026, 17:28 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6 mrt 2026, 17:20 UTC

Marktinformatie

Winsten

Auto & Transport Roundup: Market Talk

6 mrt 2026, 17:20 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Pliant Therapeutics Inc Prognose

Koersdoel

By TipRanks

55.04% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2 USD 55.04%

Hoogste 2 USD

Laagste 2 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pliant Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Pliant Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.43 / 1.6Steun & Weerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.